Sign In
Buy GKOS
$113.64
+2.86 (+2.58%)
At Close: Jun 03, 2026
Principal Financial Group Inc. Reduces Stock Position in Glaukos Corporation $GKOS
05:02am, Sunday, 08'th Feb 2026
Principal Financial Group Inc. cut its holdings in Glaukos Corporation (NYSE: GKOS) by 2.2% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchang
Alger Weatherbie Specialized Growth Fund Q4 2025 Winners And Laggards
10:00am, Tuesday, 03'rd Feb 2026
Class A shares of the Alger Weatherbie Specialized Growth Fund outperformed the Russell 2500 Growth Index during the fourth quarter of 2025. Natera, Inc., ACADIA Pharmaceuticals Inc., and Glaukos Corp
Director Sells GKOS 15,000 Shares for $1.9 Million
04:46pm, Saturday, 31'st Jan 2026
15,000 shares were exercised as options and immediately sold in the open market for a total of ~$1.9 million at around $127.71 per share on Jan. 22, 2026. This transaction represented 28.60% of Staple
Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance
10:30pm, Thursday, 29'th Jan 2026
From a sector perspective, strength within Industrials and Information Technology offset relative weakness in Health Care. The October earnings report reinforced confidence in Comfort Systems' ability
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
09:36am, Thursday, 29'th Jan 2026
GKOS is positioned for growth as interventional glaucoma adoption expands, iDose and iStent synergies build, and scale drives operating leverage despite margin pressures.
Glaukos (NYSE:GKOS) Stock Price Up 6% Following Analyst Upgrade
01:32am, Thursday, 29'th Jan 2026
Shares of Glaukos Corporation (NYSE: GKOS - Get Free Report) were up 6% on Wednesday after BTIG Research raised their price target on the stock from $123.00 to $131.00. BTIG Research currently has a b
Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR
07:00am, Wednesday, 28'th Jan 2026
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders,
Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17
07:00am, Tuesday, 20'th Jan 2026
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Glaukos Corporation (GKOS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
11:55pm, Tuesday, 13'th Jan 2026
Glaukos Corporation (GKOS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance
04:05pm, Tuesday, 13'th Jan 2026
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders,
Glaukos Corporation (NYSE:GKOS) Given Consensus Recommendation of “Moderate Buy” by Brokerages
01:55am, Sunday, 04'th Jan 2026
Shares of Glaukos Corporation (NYSE: GKOS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the sixteen analysts that are covering the stock, MarketBeat Ratings reports. Two equ
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
09:55am, Monday, 29'th Dec 2025
GKOS appears well-positioned for long-term growth as iDose TR adoption accelerates and Epioxa secures FDA approval, although reimbursement and execution risks remain.
Glaukos Corporation $GKOS Shares Sold by Texas Permanent School Fund Corp
05:18am, Monday, 22'nd Dec 2025
Texas Permanent School Fund Corp reduced its position in shares of Glaukos Corporation (NYSE: GKOS) by 70.4% during the second quarter, according to the company in its most recent Form 13F filing with
Glaukos Announces Participation in J.P. Morgan Healthcare Conference
07:00am, Tuesday, 16'th Dec 2025
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Glaukos Corporation (GKOS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
05:23pm, Wednesday, 03'rd Dec 2025
Glaukos Corporation (GKOS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
